NCT02401880View on ClinicalTrials.gov

Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Linagliptin

22 subjects will receive Linagliptin for 30 days

OTHER

Placebo

22 subjects will receive Placebo for 30 days

DRUG

Empagliflozin

44 subjects will receive Empagliflozin for 60 days

Trial Locations (2)

41460

Profil Institut für Stoffwechselforschung GmbH, Neuss

55116

Profil Mainz GmbH & Co. KG, Mainz

All Listed Sponsors
lead

Profil Institut für Stoffwechselforschung GmbH

INDUSTRY

NCT02401880 - Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology | Biotech Hunter | Biotech Hunter